EUROMACS第二份儿童机械循环支持报告
结果显示12个月生存率81.5%,移植率6个月为33.2%,低龄(<1岁)和低体重(<20 kg)患者生存率较低。
要点
- 儿童VAD植入后12个月生存率为81.5%,早期与后期生存率无显著差异。
- 6个月移植率仅33.2%,12个月为46.7%,8.7%脱离装置。
- 年龄<1岁(P=0.01)和体重<20 kg(P=0.015)与较低生存率相关。
核心结论
- 儿童VAD植入后12个月总生存率为81.5%,早期与后期生存率无显著差异。
- 低龄(<1岁)和低体重(<20 kg)患者生存率较低。
- 6个月移植率仍较低,为33.2%。
研究设计与样本
- EUROMACS注册数据库的第二次儿童报告,由欧洲心胸外科协会运作。
主要发现
- 398例植入在353例患者中(150例女性,203例男性)。
- 心衰病因最常见为心肌病(61%),先天性心脏病16.4%,心肌炎16.1%。
- 竞争结局分析显示80%存活至移植、恢复或仍在支持中,2年随访时20%在支持中死亡。
- 12个月时46.7%接受移植,8.7%脱离装置,18.5%死亡。
- 3个月不良事件率:装置故障(包括泵更换)1.69/患者年,大出血0.48,严重感染0.64,神经事件0.78。
关键数值与推荐
- 12个月生存率81.5%。
- 6个月移植率33.2%,12个月移植率46.7%。
- 年龄<1岁与较低生存率相关(P=0.01),体重<20 kg与较低生存率相关(P=0.015)。
- 3个月不良事件率:装置故障1.69/患者年,大出血0.48/患者年,严重感染0.64/患者年,神经事件0.78/患者年。
临床怎么用
- 儿童VAD治疗需关注低龄和低体重患者的预后风险。
- 注册数据可用于质量改进和 outcomes 监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A second paediatric report has been generated from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). The purpose of EUROMACS, which is operated by the European Association for Cardio-Thoracic Surgery, is to gather data related to durable mechanical circulatory support for scientific purposes and to publish reports with respect to the course of mechanical circulatory support therapy. Since the first report issued, efforts to increase compliance and participation have been extended. Additionally, the data provided the opportunity to analyse patients of younger age and lower weight. METHODS: Participating hospitals contributed pre-, peri- and long-term postoperative data on mechanical circulatory support implants to the registry. Data for all implants in paediatric patients (≤19 years of age) performed from 1 January 2000 to 1 July 2019 were analysed. This report includes updates of patient characteristics, implant frequency, outcome (including mortality rates, transplants and recovery rates) as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding. RESULTS: Twenty-nine hospitals contributed 398 registered implants in 353 patients (150 female, 203 male) to the registry. The most frequent aetiology of heart failure was any form of cardiomyopathy (61%), followed by congenital heart disease and myocarditis (16.4% and 16.1%, respectively). Competing outcomes analysis revealed that a total of 80% survived to transplant or recovery or are ongoing; at the 2-year follow-up examination, 20% died while on support. At 12 months, 46.7% received transplants, 8.7% were weaned from their device and 18.5% died. The 3-month adverse events rate was 1.69 per patient-year for device malfunction including pump exchange, 0.48 for major bleeding, 0.64 for major infection and 0.78 for neurological events. CONCLUSIONS: The overall survival rate was 81.5% at 12 months following ventricular assist device implant. The comparison of survival rates of the early and later eras shows no significant difference. A focus on specific subgroups showed that survival was less in patients of younger age (<1 year of age) (P = 0.01) and lower weight (<20 kg) (P = 0.015). Transplant rates at 6 months continue to be low (33.2%) The fact that the EUROMACS registry is embedded within the European Association for Cardio-Thoracic Surgery Quality Improvement Programme offers opportunities to focus on improving outcomes.
引用
- de By TMMH, Antonides CFJ, Schweiger M, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): second EUROMACS Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2020. PMID: 32364221. doi:10.1093/ejcts/ezaa132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。